Align Technology Launches Integrated Consumer and Professional Brand Campaign Focused on Invisalign ® Treatment for Kids and Teens
TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. ('Align') (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign ® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced integrated global professional and consumer campaigns to highlight the unique needs of growing patients and treatment options for meeting those needs and creating new smiles with the Invisalign clear aligner system.
As the leader in digital orthodontics, Align has developed an extensive end-to-end portfolio that helps doctors treat a range of case types including the most complex cases, and growing patients and kids as young as 6.
Share
'We are proud to launch these complementary Invisalign ® brand campaigns about the kid and teen-friendly orthodontic solutions from the #1 doctor-recommended clear aligner brand, 1 ' said Kamal Bhandal, senior vice president, Global Brand, Consumer and Americas Marketing. 'Our new 'Invisalign for Kids' brand consumer campaign is designed to increase awareness with parents that Invisalign aligners are an effective solution for kids and educate parents about the benefits of Invisalign treatment for kids and teens, including Invisalign ® Palatal Expander System, Invisalign First™, Invisalign ® System with mandibular advancement, as well as Invisalign ® Virtual Care to help parents monitor progress – all designed to deliver predictable results and a positive experience for growing children.'
The aspects of Invisalign treatment, from Phase 1 to comprehensive Phase 2, to retention are designed for predictable results and a positive experience while addressing the unique needs of growing children. And with Invisalign aligners, children can enjoy their favorite foods, keep up their oral hygiene, maintain an active lifestyle, and smile and build their confidence.
At the same time, our companion Invisalign 'Growing Patients' professional campaign provides doctors with information and awareness about the dedicated range of Invisalign treatment options designed specifically for children and teens from well-established products such as Invisalign First™ aligners to the latest additions in the growing patient product portfolio, including the Invisalign ® Palatal Expander System and Invisalign ® System with mandibular advancement featuring occlusal blocks ('MAOB').
Doctors can use the Invisalign System to treat nearly any orthodontic case, from children through teens to adults, at the different stages of their growth. Even with some baby teeth, it may be the perfect time for children ages 6 to 10 to start Phase 1 orthodontic treatment. According to the American Association of Orthodontists ('AAO'), children should get screened by an orthodontist by age 7. 2
Phase 1 treatment takes advantage of a child's normal development to help bones in the face and mouth grow correctly and reduce the need for more extensive treatment later. Once most permanent teeth are in place, Phase 2 treatment focuses on ensuring teeth are in their proper place for a healthy bite and a pleasing appearance. 3
'As kids and teens age and grow, orthodontic treatment needs to address both tooth movement and dental facial orthopedic or skeletal movement,' said Dr. Mitra Derakhshan, executive vice president, chief clinical officer, Global Treatment Planning and Clinical Services. 'As the leader in digital orthodontics, Align has developed an extensive end-to-end portfolio that helps doctors treat a range of case types including the most complex cases, and growing patients and kids as young as 6. I believe our new 'Invisalign for Kids' brand and 'Growing Patients' campaigns will help increase confidence in Invisalign treatment for the largest segment of the orthodontic market and drive further adoption among growing patients.'
This latest announcement is part of Align's long-term investment in the growing patients' segment of the market which has included multiple innovation milestones over 20 million smiles.
Overview of Invisalign products for growing patients:
2008: Invisalign ® Teen – Teen specific features to address patient compliance, natural eruption of permanent teeth, and root-movement control – issues that are common in treatment of younger patients.
2017: Invisalign ® System with mandibular advancement – the first clear aligner solution designed for simultaneous Class II correction and alignment in growing tween and teen patients and Invisalign ® System with mandibular advancement featuring enhanced precision wings.
2018: Invisalign First™ – the first clear aligner treatment with features designed specifically to address a broad range of indications in mixed-dentition patients, including shorter clinical crowns, management of erupting dentition, and predictable dental arch expansion.
2023: Invisalign ® Palatal Expander System –Align's first direct 3D printed orthodontic device, provides a safe, comfortable, and clinically effective 4 alternative to traditional palatal expanders that require manually turning a screw in the device in the mouth daily to achieve skeletal expansion.
2025: Invisalign ® System with mandibular advancement featuring occlusal blocks – Align's first clear aligner product with integrated solid occlusal blocks that delivers predictable mandibular advancement. Invisalign occlusal blocks provide durability, improve engagement, and enable vertical opening to offer earlier advancement of the mandible in cases like Class II deep bite to improve treatment efficiency.
'Our commitment is to support our doctors in treating patients through every step of their journey – from first visit to a lasting smile. More than 28 years of anonymized data from more than 20 million Invisalign ® patients treated globally have helped Align develop our integrated suite of innovative products and solutions that enable doctors to treat patients over their continuum of care,' said Michael Smith, Align vice president, Product Management. 'This new integrated campaign highlights the unique product offerings within our growing patient portfolio and how we are innovating in digital orthodontics to empower doctors to transform smiles and change lives.'
1. Based on a global survey of 1,786 doctors (dentists and orthodontists who use clear aligners) by IQVIA in NA, EMEA, LATAM, and APAC. Data on File at Align Technology, as of June 30, 2022.
2. American Academy of Orthodontists. The Right Time: When Should Your Child See an Orthodontist? (https://aaoinfo.org/whats-trending/when-should-your-child-see-an-orthodontist/) Accessed 2/26/24.
3. American Academy of Orthodontists. Embarking on a Two Phase Orthodontic Adventure (https://aaoinfo.org/whats-trending/6-facts-about-two-phase-treatment/) Accessed 2/28/24.
4. Based on a survey in August 2023 in Canada of 10 Invisalign trained orthodontists who participated in the Invisalign Palatal Expander System Technical Design Assessment and have treated at least 1 patient age 6-11 years with IPE. Data on file at Align Technology, Inc. as of October 30, 2023.
About Align Technology, Inc.
Align Technology designs and manufactures the Invisalign ® System, the most advanced clear aligner system in the world, iTero™ intraoral scanners and services, and exocad™ CAD/CAM software. These technology building blocks enable enhanced digital orthodontic and restorative workflows to improve patient outcomes and practice efficiencies for over 281.4 thousand doctor customers and are key to accessing Align's 600 million consumer market opportunity worldwide. Over the past 28 years, Align has helped doctors treat over 20.1 million patients with the Invisalign System and is driving the evolution in digital dentistry through the Align™ Digital Platform, our integrated suite of unique, proprietary technologies and services delivered as a seamless, end-to-end solution for patients and consumers, orthodontists and GP dentists, and lab/partners. Visit www.aligntech.com for more information.
For additional information about the Invisalign System or to find an Invisalign doctor in your area, please visit www.invisalign.com. For additional information about the iTero digital scanning system, please visit www.itero.com. For additional information about exocad dental CAD/CAM offerings and a list of exocad reseller partners, please visit www.exocad.com.
Invisalign, iTero, exocad, Align, Align Digital Platform and iTero Lumina are trademarks of Align Technology, Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
Biomea Fusion Announces Pricing of Public Offering of Securities
REDWOOD CITY, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ('Biomea') (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced the pricing of its previously announced underwritten public offering consisting of (i) 19,450,000 shares of its common stock and accompanying warrants to purchase an aggregate of 19,450,000 shares of common stock (or pre-funded warrants in lieu thereof) and (ii) in lieu of common stock, to certain investors, pre-funded warrants to purchase an aggregate of up to 550,000 shares of its common stock and accompanying warrants to purchase an aggregate of 550,000 shares of common stock (or pre-funded warrants in lieu thereof), at an exercise price of $0.0001 per pre-funded warrant. In addition, Biomea has granted the underwriters a 30-day option to purchase up to an additional 3,000,000 shares of common stock and/or warrants at the public offering price, less underwriting discounts and commissions. The common stock and pre-funded warrants are being sold in combination with an accompanying warrant to purchase one share of common stock (or a pre-funded warrant in lieu thereof) issued for each share of common stock or pre-funded warrant sold. The accompanying warrant has an exercise price of $2.50 per share, is immediately exercisable from the date of issuance and will expire eighteen months from the date of issuance. The combined offering price of each share of common stock and accompanying common stock warrant is $2.00. The combined offering price of each pre-funded warrant and accompanying common stock warrant is $1.9999. All of the shares, pre-funded warrants and accompanying common stock warrants in the offering are being sold by Biomea. The gross proceeds to Biomea from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $40 million, excluding any exercise of the underwriters' option to purchase additional shares and/or warrants. The offering is expected to close on June 20, 2025, subject to the satisfaction of customary closing conditions. Jefferies is acting as sole book-running manager for the offering The shares of common stock, pre-funded warrants and common stock warrants and shares of common stock issuable upon the exercise of the pre-funded warrants and common stock warrants are being offered by Biomea pursuant to an effective shelf registration statement on Form S-3 (File No. 333-267884), that was previously filed with the U.S. Securities and Exchange Commission ('SEC') on October 14, 2022 and declared effective on October 24, 2022. A preliminary prospectus supplement relating to and describing the terms of the offering was filed with the SEC on June 17, 2025 and is available for free on the SEC's website located at The final prospectus supplement and accompanying prospectus relating to and describing the terms of the offering will be filed with the SEC and will be available for free on the SEC's website located at Copies of the final prospectus supplement and the accompanying prospectus relating to the offering, when available, may also be obtained from: Jefferies LLC by mail at Attn: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 821-7388, or by email at prospectus_department@ or by accessing the SEC's website at This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Biomea FusionBiomea Fusion is a clinical-stage diabetes and obesity medicines company focused on the development of its oral small molecules, icovamenib and BMF-650, both designed to significantly improve the lives of patients with diabetes, obesity, and metabolic diseases. Visit us at and follow us on LinkedIn, X and Facebook. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding Biomea's beliefs and expectations regarding the anticipated public offering; uncertainties related to market conditions and statements regarding timing, size and expected proceeds of the proposed offering, and Biomea's research, development and regulatory plans, the progress of ongoing and upcoming clinical trials and the timing of such events. The words 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'target' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs of future events and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to completion of the public offering on the anticipated terms, or at all, market conditions and statements regarding the expected gross proceeds of the offering, timing of closing of the offering, the satisfaction of customary closing conditions related to the offering and sale of securities and Biomea's ability to complete the offering. These and other risks and uncertainties are described in greater detail in the section entitled 'Risk Factors' in Biomea's most recent annual report on Form 10-K filed on March 31, 2025 and subsequent quarterly reports on Form 10-Q, filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in Biomea's other filings with the SEC, including those contained or incorporated by reference in the preliminary prospectus supplement and accompanying prospectus related to the offering filed with the SEC. Any forward-looking statements contained in this press release represent Biomea's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Biomea explicitly disclaims any obligation to update any forward-looking statements, except as required by law. Contact:Meichiel Jennifer WeissSr. Director, Investor Relations and Corporate DevelopmentIR@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
17 minutes ago
- Business Insider
Shyft Group shareholders approve merger with Aebi Schmidt Group
The Shyft Group (SHYF) announced its shareholders have voted to approve and adopt the merger agreement relating to the proposed merger with an indirect, wholly owned subsidiary of Aebi Schmidt Group. Approximately 99% of the shares voted were cast in favor of the transaction. The transaction is expected to close on or around July 1, subject to customary closing conditions. Upon consummation, the combined company will operate as 'Aebi Schmidt Group' and is expected to trade on NASDAQ under 'AEBI' around July 1. Confident Investing Starts Here:
Business Wire
33 minutes ago
- Business Wire
Mitsubishi Electric Develops Edge-device Language Model for Domain-specific Manufacturing
TOKYO--(BUSINESS WIRE)-- Mitsubishi Electric Corporation (TOKYO: 6503) announced today that it has developed a language model tailored for manufacturing processes operating on edge devices. The Maisart ® -branded AI technology has been pre-trained with data from Mitsubishi Electric's internal operations, enabling it to support a wide range of applications in specific manufacturing domains. In addition, the model leverages a uniquely developed data-augmentation technique to generate responses optimized for user-specific applications. The widespread adoption of generative AI is accelerating the use of large language models (LLMs). However, the significant computational and energy costs associated with LLMs are a growing concern. Additionally, there is increasing demand for generative AI solutions that can operate in on-premises environments due to data privacy and confidential information management requirements. In response, Mitsubishi Electric has developed a domain-specific language model by training a publicly available Japanese base model with the company's proprietary data from its own business domains, including factory automation (FA). Using training data generated through the company's original augmentation techniques enabled effective, task-specific fine-tuning. The resulting model is compact enough to run on limited hardware resources, making it suitable for environments with constrained computing capabilities such as edge devices, as well as for on-premises operations such as call centers that handle sensitive customer information.
